Search

Your search keyword '"Rosenthal, Norman"' showing total 660 results
Start Over Author "Rosenthal, Norman"
660 results on '"Rosenthal, Norman"'

4. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Author

Oshima, Megumi, Jardine, Meg J., Agarwal, Rajiv, Bakris, George, Cannon, Christopher P., Charytan, David M., de Zeeuw, Dick, Edwards, Robert, Greene, Tom, Levin, Adeera, Lim, Soo Kun, Mahaffey, Kenneth W., Neal, Bruce, Pollock, Carol, Rosenthal, Norman, Wheeler, David C., Zhang, Hong, Zinman, Bernard, Perkovic, Vlado, and Heerspink, Hiddo J.L.

Published
2021
Full Text
View/download PDF

8. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial

Author

Mahaffey, Kenneth W., Jardine, Meg J., Bompoint, Severine, Cannon, Christopher P., Neal, Bruce, Heerspink, Hiddo J.L., Charytan, David M., Edwards, Robert, Agarwal, Rajiv, Bakris, George, Bull, Scott, Capuano, George, de Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Sun, Tao, Wheeler, David C., Yavin, Yshai, Zhang, Hong, Zinman, Bernard, Rosenthal, Norman, Brenner, Barry M., and Perkovic, Vlado

Published
2019
Full Text
View/download PDF

11. Poetry Points the way: 'Remember, poetry is free and has no side effects'

Author

Rosenthal, Norman E.

Subjects
Poetry -- Appreciation -- Psychological aspects, General interest, News, opinion and commentary
Abstract

CAN POETRY really have a profound effect on your life? Can words on a page, perhaps written many years ago, have the power to make a difference? Let me show [...]

Published
2022

12. Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)

Author

Ferrannini, Ele, primary, Baldi, Simona, additional, Scozzaro, Tiziana, additional, Tsimihodimos, Vasilis, additional, Tesfaye, Fisseha, additional, Shaw, Wayne, additional, Rosenthal, Norman, additional, Figtree, Gemma A., additional, Neal, Bruce, additional, Mahaffey, Kenneth W., additional, Perkovic, Vlado, additional, and Hansen, Michael K., additional

Published
2022
Full Text
View/download PDF

14. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-7 PREDICTS CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: THE CREDENCE TRIAL

Author

Januzzi, James L., primary, Butler, Javed, additional, Sattar, Naveed, additional, Tefera, Eshetu, additional, Rosenthal, Norman, additional, Yavin, Yshai, additional, Bull, Scott, additional, Jardine, Meg, additional, Pollock, Carol, additional, Heerspink, Hiddo J.L., additional, and Hansen, Michael K., additional

Published
2022
Full Text
View/download PDF

15. Additional file 4 of Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program

Author

Ferrannini, Giulia, Rosenthal, Norman, Hansen, Michael K., and Ferrannini, Ele

Abstract

Additional file 4: Table S1. LFT levels at baseline and 2 years by treatment*. Table S2. Univariate association (Spearman’s r or Wilcoxon test) of baseline LFTs with clinical characteristics. Table S3. Association with CV and renal outcomes (HR [95% C.I.]) of canagliflozin treatment alone, treatment adjusted for the covariates,* and treatment further adjusted for 5 updated LFTs. Table S4. Multivariate association (HR [95% CI]) of AST/ALT + treatment with CV and renal outcomes*.

Published
2022
Full Text
View/download PDF

18. Art censorship

Author

Fitzpatrick, James, Rosenthal, Norman, and Chapman, Jake

Published
2002

19. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

Author

Neuen, Brendon L, primary, Oshima, Megumi, additional, Perkovic, Vlado, additional, Agarwal, Rajiv, additional, Arnott, Clare, additional, Bakris, George, additional, Cannon, Christopher P, additional, Charytan, David M, additional, Edwards, Robert, additional, Górriz, Jose L, additional, Jardine, Meg J, additional, Levin, Adeera, additional, Neal, Bruce, additional, De Nicola, Luca, additional, Pollock, Carol, additional, Rosenthal, Norman, additional, Wheeler, David C, additional, Mahaffey, Kenneth W, additional, and Heerspink, Hiddo J L, additional

Published
2021
Full Text
View/download PDF

21. Effects of Canagliflozin in Patients with Baseline eGFR: Subgroup Analysis of the Randomized CREDENCE Trial

Author

Bakris, George, Oshima, Megumi, Mahaffey, Kenneth W, Agarwal, Rajiv, Cannon, Christopher P, Capuano, George, Charytan, David M, de Zeeuw, Dick, Edwards, Robert, Greene, Tom, Heerspink, Hiddo J L, Levin, Adeera, Neal, Bruce, Oh, Richard, Pollock, Carol, Rosenthal, Norman, Wheeler, David C, Zhang, Hong, Zinman, Bernard, Jardine, Meg J, Perkovic, Vlado, Groningen Kidney Center (GKC), and Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)

Abstract

BACKGROUND AND OBJECTIVES: The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduced the risk of kidney failure and cardiovascular events in participants with type 2 diabetes mellitus and CKD. Little is known about the use of SGLT2 inhibitors in patients with eGFR 300-5000 mg/g, and an eGFR of 30 to 0.20). The estimate for kidney failure in participants with eGFR 0.12). CONCLUSIONS: This post hoc analysis suggests canagliflozin slowed progression of kidney disease, without increasing AKI, even in participants with eGFR

Published
2020

22. The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial

Author

Arnott, Clare, primary, Li, Jing‐Wei, additional, Cannon, Christopher P., additional, Zeeuw, Dick, additional, Neuen, Brendon L., additional, Heerspink, Hiddo J. L., additional, Charytan, David M., additional, Agarwal, Anubha, additional, Huffman, Mark D., additional, Figtree, Gemma A., additional, Bakris, George, additional, Chang, Tara I‐Hsin, additional, Feng, Kent, additional, Rosenthal, Norman, additional, Zinman, Bernard, additional, Jardine, Meg J., additional, Perkovic, Vlado, additional, Neal, Bruce, additional, and Mahaffey, Kenneth W., additional

Published
2021
Full Text
View/download PDF

23. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial

Author

Yu, Jie, primary, Li, Jingwei, additional, Leaver, Phillip J, additional, Arnott, Clare, additional, Huffman, Mark D, additional, Udell, Jacob A, additional, Perkovic, Vlado, additional, Mahaffey, Kenneth W, additional, de Zeeuw, Dick, additional, Fulcher, Greg, additional, Matthews, David R, additional, Shaw, Wayne, additional, Rosenthal, Norman, additional, Neal, Bruce, additional, and Figtree, Gemma A, additional

Published
2021
Full Text
View/download PDF

25. THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL

Author

Arnott, Clare, Li, Jing-Wei, Cannon, Christopher P., Neuen, Brendon, Heerspink, Hiddo L., Neal, Bruce, Charytan, David M., Agarwal, Rajiv, Bakris, George L., De Zeeuw, Dick, Greene, Tom, Levin, Adeera, Pollock, Carol, Chang, Tara, Rosenthal, Norman, Zhang, Hong, Zinman, Bernard, Perkovic, Vlado, Jardine, Meg, Mahaffey, Kenneth, Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), and Groningen Kidney Center (GKC)

Published
2020

26. EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

Author

Neuen, Brendon, Mahaffey, Kenneth, Cannon, Christopher P., Jardine, Meg, Heerspink, Hiddo L., Neal, Bruce, Arnott, Clare, Zhou, Zien, Charytan, David M., Agarwal, Rajiv, Bakris, George L., De Zeeuw, Dick, Greene, Tom, Levin, Adeera, Wheeler, David C., Rosenthal, Norman, Zhang, Hong, Zinman, Bernard, Perkovic, Vlado, Pollock, Carol, Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), and Groningen Kidney Center (GKC)

Published
2020

27. Topiramate for treating alcohol dependence: a randomized controlled trial

Author

Johnson, Bankole A., Rosenthal, Norman, Capece, Julie A., Wiegand, Frank, Lian Mao, McKay, Amy, Beyers, Karen, Ait-Daoud, Nassima, Ciraulo, Domenic A., Kranzler, Henry R., Mann, Karl, Anton, Raymond F., O'Malley, Stephanie S., and Swift, Robert M.

Subjects
Topiramate -- Dosage and administration, Alcoholism -- Drug therapy, Alcoholism -- Care and treatment
Abstract

A study investigates if topiramate is a safe and effective treatment for alcohol dependence. Results show that topiramate is significantly efficacious in treating alcohol dependence.

Published
2007

29. Binge-eating disorder as a distinct familial phenotype in obese individuals

Author

Hudson, James I., Lalonde, Justine K., Berry, Judith M., Pindyck, Lindsay J., Bulik, Cynthia M., Crow, Scott J., McElroy, Susan L., Laird, Nan M., Tsuang, Ming T., Walsh, B. Timothy, Rosenthal, Norman R., and Pope, Harrison G., Jr.

Subjects
Compulsive eating -- Genetic aspects, Obesity -- Genetic aspects, Obesity -- Risk factors, Phenotype -- Research, Health, Psychology and mental health
Published
2006

30. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder

Author

DelBello, Melissa P., Findling, Robert L., Kushner, Stuart, Wang, Daniel, Olson, William H., Capece, Julie A., Fazzio, Lydia, and Rosenthal, Norman R.

Subjects
Topiramate -- Research, Child psychiatry -- Research, Bipolar disorder -- Drug therapy, Bipolar disorder -- Research, Anticonvulsants -- Usage, Adolescent psychiatry -- Research, Family and marriage, Psychology and mental health, American Academy of Child and Adolescent Psychiatry
Published
2005

31. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.

Author

Yu, Jie, Li, Jingwei, Leaver, Phillip J, Arnott, Clare, Huffman, Mark D, Udell, Jacob A, Perkovic, Vlado, Mahaffey, Kenneth W, Zeeuw, Dick de, Fulcher, Greg, Matthews, David R, Shaw, Wayne, Rosenthal, Norman, Neal, Bruce, and Figtree, Gemma A

Subjects
MYOCARDIAL infarction, ST elevation myocardial infarction, CANAGLIFLOZIN, TYPE 2 diabetes, CHRONIC kidney failure
Abstract

Aims Given the benefits of sodium glucose co-transporter 2 inhibition (SGLT2i) in protecting against heart failure in diabetic patients, we sought to explore the potential impact of SGLT2i on the clinical features of patients presenting with myocardial infarction (MI) through a post hoc analysis of CANVAS Programme and CREDENCE trial. Methods and results Individuals with type 2 diabetes and history or high risk of cardiovascular disease (CANVAS Programme) or type 2 diabetes and chronic kidney disease (CREDENCE) were included. The intervention was canagliflozin 100 or 300 mg (combined in the analysis) or placebo. MI events were adjudicated as ST-elevation myocardial infarction (STEMI), non-STEMI, and type 1 MI or type 2 MI. A total of 421 first MI events in the CANVAS Programme and 178 first MI events in the CREDENCE trial were recorded (83 fatal, 128 STEMI, 431 non-STEMI, and 40 unknown). No benefit of canagliflozin compared with placebo on time to first MI event was observed [hazard ratio (HR) 0.89; 95% confidence interval (CI) 0.75, 1.05]. Canagliflozin was associated with lower risk for non-STEMI (HR 0.78; 95% CI 0.65, 0.95) but suggested a possible increase in STEMI (HR 1.55; 95% CI 1.06, 2.27), with no difference in risk of type 1 or type 2 MI. There was no change in fatal MI (HR 1.22, 95% CI 0.78, 1.93). Conclusion Canagliflozin was not associated with a reduction in overall MI in the pooled CANVAS Programme and CREDENCE trial population. The possible differential effect on STEMI and Non-STEMI observed in the CANVAS cohort warrants further investigation. Trial registration ClinicalTrials.gov identifiers: NCT01032629, NCT01989754, and NCT02065791. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

35. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2

Author

Bakris, George, primary, Oshima, Megumi, additional, Mahaffey, Kenneth W., additional, Agarwal, Rajiv, additional, Cannon, Christopher P., additional, Capuano, George, additional, Charytan, David M., additional, de Zeeuw, Dick, additional, Edwards, Robert, additional, Greene, Tom, additional, Heerspink, Hiddo J.L., additional, Levin, Adeera, additional, Neal, Bruce, additional, Oh, Richard, additional, Pollock, Carol, additional, Rosenthal, Norman, additional, Wheeler, David C., additional, Zhang, Hong, additional, Zinman, Bernard, additional, Jardine, Meg J., additional, and Perkovic, Vlado, additional

Published
2020
Full Text
View/download PDF

38. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program

Author

Arnott, Clare, primary, Neuen, Brendon L., additional, Heerspink, Hiddo J.L., additional, Figtree, Gemma A., additional, Kosiborod, Mikhail, additional, Lam, Carolyn S., additional, Cannon, Christopher P., additional, Rosenthal, Norman, additional, Shaw, Wayne, additional, Mahaffey, Kenneth W., additional, Jardine, Meg J., additional, Perkovic, Vlado, additional, and Neal, Bruce, additional

Published
2020
Full Text
View/download PDF

39. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial

Author

Oshima, Megumi, primary, Neuen, Brendon L., additional, Li, JingWei, additional, Perkovic, Vlado, additional, Charytan, David M., additional, de Zeeuw, Dick, additional, Edwards, Robert, additional, Greene, Tom, additional, Levin, Adeera, additional, Mahaffey, Kenneth W., additional, De Nicola, Luca, additional, Pollock, Carol, additional, Rosenthal, Norman, additional, Wheeler, David C., additional, Jardine, Meg J., additional, and Heerspink, Hiddo J.L., additional

Published
2020
Full Text
View/download PDF

40. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial

Author

Arnott, Clare, primary, Huang, Yuli, additional, Neuen, Brendon L, additional, Di Tanna, Gian Luca, additional, Cannon, Christopher P., additional, Oh, Richard, additional, Edwards, Robert, additional, Kavalam, Mary, additional, Rosenthal, Norman, additional, Perkovic, Vlado, additional, Jardine, Meg J, additional, Mahaffey, Kenneth, additional, and Neal, Bruce, additional

Published
2020
Full Text
View/download PDF

41. Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study

Author

Yuan, Zhong, primary, DeFalco, Frank, additional, Wang, Lu, additional, Hester, Laura, additional, Weaver, James, additional, Swerdel, Joel N., additional, Freedman, Amy, additional, Ryan, Patrick, additional, Schuemie, Martijn, additional, Qiu, Rose, additional, Yee, Jacqueline, additional, Meininger, Gary, additional, Berlin, Jesse A., additional, and Rosenthal, Norman, additional

Published
2020
Full Text
View/download PDF

46. Binge Eating Disorder: A Stable Syndrome

Author

Pope, Harrison G., Jr., Lalonde, Justine K., Pindyck, Lindsay J., Walsh, Timothy, Bulik, Cynthia M., Crow, Scott J., McElroy, Susan L., Rosenthal, Norman, and Hudson, James I.

Published
2006

47. A controlled trial of light therapy for the treatment of pediatric seasonal affective disorder

Author

Swedo, Susan E., Allen, Albert John, Glod, Carol A., Clark, Catherine H., Teicher, Martin H., Richter, Dan, Hoffman, Cara, Hamburger, Susan D., Dow, Sara, Brown, Charlotte, and Rosenthal, Norman E.

Subjects
Phototherapy -- Research, Seasonal affective disorder -- Care and treatment, Children -- Psychological aspects, Family and marriage, Psychology and mental health
Published
1997

Catalog

Books, media, physical & digital resources
See catalog results